Publications by authors named "Simona Frezzini"

Claim this Profile
[
[Sacituzumab govitecan in a triple-negative breast cancer patient journey: a cutting-edge story.].
Simona Frezzini

Recenti Prog Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP Inhibitors in Brain Metastases from Epithelial Ovarian Cancer through a Multimodal Patient Journey: Case Reports and Literature Review.
Simona Frezzini, Giulia Tasca, Lucia Borgato, Lucia Sartor, Annamaria Ferrero

Int J Mol Sci· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spotlight on New Hallmarks of Drug-Resistance towards Personalized Care for Epithelial Ovarian Cancer.
Simona Frezzini, Sara Lonardi

Cells· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach.
Caterina Fontanella, Carlo Alberto Giorgi, Stefania Russo, Silvia Angelini, Linda Nicolardi, Simona Frezzini

Crit Rev Oncol Hematol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Raimondo Di Liello, Laura Arenare, Francesco Raspagliesi, Giovanni Scambia, Carmela Pisano, Simona Frezzini

Int J Gynecol Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Simona Frezzini

Int J Gynecol Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Sandro Pignata, Domenica Lorusso, Florence Joly, Ciro Gallo, Nicoletta Colombo, Simona Frezzini

Lancet Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study.
Tommaso Giarratano, Simona Frezzini, Monica Zanocco, Carlo Alberto Giorgi, Eleonora Mioranza

Breast J· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the Genomic Profile of Cancer Stem Cells and Their Non-Stem Counterpart: The Case of Ovarian Cancer.
Elena Laura Mazzoldi, Anna Pastò, Giorgia Pilotto, Sonia Minuzzo, Ilaria Piga, Simona Frezzini

J Clin Med· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.
Nicoletta Colombo, Eleonora Zaccarelli, Alessandra Baldoni, Simona Frezzini, Giovanni Scambia

Br J Cancer· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease.
Maria Vittoria Dieci, Vassilena Tsvetkova, Gaia Griguolo, Federica Miglietta, Mara Mantiero, Simona Frezzini

Front Oncol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A juxtacrine/paracrine loop between C-Kit and stem cell factor promotes cancer stem cell survival in epithelial ovarian cancer.
Elena Laura Mazzoldi, Simona Pavan, Giorgia Pilotto, Kevin Leone, Anna Pagotto, Simona Frezzini

Cell Death Dis· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autophagy inhibition reduces chemoresistance and tumorigenic potential of human ovarian cancer stem cells.
Anna Pagotto, Giorgia Pilotto, Elena Laura Mazzoldi, Maria Ornella Nicoletto, Simona Frezzini

Cell Death Dis· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis